Last Updated on October 6, 2024 by The Health Master
Granules India announced that the US Food & Drug Administration (USFDA) has approved its Abbreviated New Drug Application (ANDA) for Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.
It is bioequivalent to the reference listed drug product (RLD), Toprol-XL Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Toprol Acquisition LLC.
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
Granules now has a total of 57 ANDA approvals from USFDA .
The current annual US market for Metoprolol Succinate ER Tablets is approximately $321 million, according to MAT Mar 2023, IQVIA/IMS Health.
USFDA gives approval for Cisatracurium Besylate injection
USFDA gives nod for Esomeprazole Magnesium Suspension
USFDA gives approval for Nitisinone capsules
USFDA gives approval for Diazepam rectal gel
USFDA gives approval for Carboprost Tromethamine Injection
USFDA gives final approval for Ephedrine Sulfate Injection
UP Govt Drafts Pharmaceutical Industry Policy 2023: Details
CDSCO implements transparent reporting system for Cough Syrup exports
Safe Disposal of Unused Drugs: Urgent Need a Comprehensive Policy
PLI Schemes Drive Rs. 21,861 crore in investments for Pharmaceuticals and Medical Devices
Drug alert: 28 out of 1302 samples declared as NSQ in May 2023
DCGI approves first indigenously developed animal-derived Class D Biomedical Device
Action to be taken against Pharmacies offering abnormal discounts: Karnataka
NPPA Guidelines: For change of Manufacturer in Notified Drug Formulations
